Black Friday Get Elite for just $149.00 Claim Now

Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer

By Fiona Craig | November 18, 2026, 6:43 AM

Erasca, Inc. (NASDAQ:ERAS) has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY) to investigate a combination treatment for patients with pancreatic cancer involving specific genetic alterations.

The agreement will evaluate Erasca’s investigational drug ERAS-0015 alongside navlimetostat (BMS-986504), a PRMT5 inhibitor developed by Bristol Myers Squibb, in patients with MTAP-deleted pancreatic ductal adenocarcinoma.

Under the terms of the collaboration, Bristol Myers Squibb will sponsor the clinical trial, while Erasca will provide ERAS-0015 for use in the study.

Both companies will retain development and commercial rights to their respective compounds, and the agreement is mutually non-exclusive, allowing each company to pursue other development opportunities.

Combination Targets RAS Mutations and PRMT5 in Pancreatic Cancer

The proposed treatment combines two investigational compounds targeting different molecular mechanisms associated with cancer development.

ERAS-0015 is an oral pan-RAS molecular glue designed to target RAS-related signalling pathways, while navlimetostat inhibits PRMT5, an enzyme involved in cellular processes that can support tumour growth.

According to Erasca, nearly all pancreatic cancers involving MTAP deletion also carry RAS mutations, providing a potential rationale for combining treatments directed at both targets.

The company believes simultaneous inhibition of RAS and PRMT5 could offer a therapeutic approach for patients with this genetically defined form of pancreatic cancer.

The planned clinical study will investigate the combination’s potential in this patient population, although its safety and effectiveness have not yet been established.

ERAS-0015 Shows Early Clinical Activity in Phase 1 Study

ERAS-0015 is currently being evaluated in the AURORAS-1 Phase 1 clinical trial, which includes patients with solid tumours carrying RAS mutations.

Preliminary results from the ongoing study have demonstrated partial responses in multiple patients across several tumour types.

According to Erasca, these responses were observed at doses as low as 8 mg administered orally once daily.

The early findings provide initial evidence of clinical activity for ERAS-0015, although further research will be required to establish its safety, optimal dosing and effectiveness across different cancer indications.

The collaboration with Bristol Myers Squibb will extend the investigation of ERAS-0015 into combination therapy for MTAP-deleted pancreatic cancer.

Erasca CEO Highlights Potential of Combination Therapy

Jonathan E. Lim, M.D., chairman, chief executive officer and co-founder of Erasca, welcomed the collaboration and pointed to the initial clinical findings for ERAS-0015.

“The early clinical activity demonstrated by ERAS-0015 has been encouraging, and we are excited to collaborate with BMS to further explore its potential in combination with navlimetostat,” Lim said.

The agreement brings together Erasca’s investigational pan-RAS treatment and Bristol Myers Squibb’s PRMT5 inhibitor as the companies explore a potential approach to treating genetically selected pancreatic cancer patients.

The study will provide an opportunity to assess whether combining the two compounds can produce clinical benefits beyond those observed with their individual mechanisms of action.

Collaboration Expands Erasca’s Clinical Development Programme

The agreement represents an expansion of Erasca’s clinical development activities as the company continues investigating ERAS-0015 across RAS-mutant cancers.

By working with Bristol Myers Squibb, Erasca will be able to evaluate its investigational compound in a combination study sponsored by a major pharmaceutical company while retaining its own development and commercial rights.

The non-exclusive structure also preserves flexibility for both companies to pursue additional research and development programmes involving their respective treatments.

Further clinical data will be needed to determine whether the combination of ERAS-0015 and navlimetostat offers a viable treatment option for patients with MTAP-deleted pancreatic ductal adenocarcinoma.

Erasca stock price

Bristol Myers Squibb stock price

Latest News

1 hour
2 hours
6 hours
Nov-17
Nov-16
Nov-13
Nov-12
Nov-12
Nov-12
Nov-12
Nov-12
Nov-12
Nov-11
Nov-10
Nov-09